Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and insights

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Catch up on the latest press releases and download media assets here

Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. Home/
    2. Media Center/
    3. Press releases /
    4. Innovative Medicine

    Innovative Medicine

    Innovative Medicine
    September 6, 2017

    ACTELION RECEIVES FDA APPROVAL OF TRACLEER® (bosentan) FOR USE IN PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    --First PAH medication approved in the U.S. for pediatric patients aged three years and older--
    Learn more
    Innovative Medicine
    September 5, 2017

    Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

    Learn more
    Innovative Medicine
    August 27, 2017

    XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study

    Learn more
    Innovative Medicine
    August 21, 2017

    New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study

    Learn more
    Innovative Medicine
    August 16, 2017

    Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments

    Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase and accelerate pace of innovation needed to make TB history
    Learn more
    Innovative Medicine
    August 2, 2017

    U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

    Learn more
    Innovative Medicine
    July 27, 2017

    Janssen Enters Collaboration with Bavarian Nordic to Develop Vaccines Against Hepatitis B Virus and HIV-1

    Collaboration to combine Janssen’s vaccine technologies with MVA-BN® technology from Bavarian Nordic to advance potential new vaccine regimens
    Learn more
    Innovative Medicine
    July 24, 2017

    Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen

    Learn more
    Innovative Medicine
    July 24, 2017

    Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine

    Learn more
    Load More